Organovo Holdings, Inc. develops NovoGen three-dimensional (3D) human tissue printing technology for creating tissue on demand for research and surgical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. serves physicians and researchers involved in the fields of cardiovascular medicine, medical research, and transplant medicine. The company was founded in 2007 and is based in San Diego, California.
Web site: http://www.organovo.com
Last updated February 16, 2012
organovo.com